EP0404097A3
Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
Abstract
The invention relates to bispecific and oligospecific, mono- and oligovalent receptors which are genetically engineered by fusion of DNA encoding F (ab) fragments of the antibodies of two or more different specificities by means of suitable linkers. Preferably, a specificity is directed either against an epitope of a tumor-associated antigen (TAA) located on the cell membrane or in the interstitium, while the other specificities relate to high molecular weight or low molecular weight ligands and, for example, complexed with ethylenediaminetetraacetate or diethylenetriamine pentaacetate in Y90 complexed form (EDTA-Y90 or DTPA-Y90). In a particularly preferred embodiment, the binding with the complexons takes place at the Komlexon receptor arm via fos-jun interaction (or even avidin-biotin interaction).
Term
Term ended
Projected expiry passed 20 June 2010, 16.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 4 of 5
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| EP0141079A2 | Cites | European Patent Office (EPO) | Y | Search report |
| EP0369566A2 | Cites | European Patent Office (EPO) | XP | Search report |
| US4652440A | Cites | United States of America | Y | Search report |
| WO8601407A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report |
| THE JOURNAL OF IMMUNOLOGY, Band 141, Nr. 11, 11. Dezember 1988, Seiten 4053-4060; C.B. BEIDLER et al.: "Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen" | Non-patent | – | – | Search report |
| TRENDS IN BIOTECHNOLOGY, Band 6, Nr. 2, Februar 1988, Seiten 36-39,42, Cambridge, GB; G. WILLIAMS: "Novel antibody reagents: production and potential" | Non-patent | – | – | Search report |
| BIOTECHNIQUES, Band 4, Nr. 3, Mai/Juni 1986, Seiten 214-221; V.T. OI et al.: "Chimeric antibodies" | Non-patent | – | – | Search report |
24 members in 14 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 3920358 | Germany | A | |
| 3920358 | Germany | A | |
| 3920358 | Germany | – | |
| DE19893920358 | – | – | – |
Members24
| Document | Office | Kind | |
|---|---|---|---|
| CA2019559A1 | Canada | A1 | |
| IE902254L | Ireland | L | |
| EP0404097A2 | European Patent Office (EPO) | A2 | |
| AU5762190A | Australia | A | |
| IE902254A1 | Ireland | A1 | |
| DE3920358A1 | Germany | A1 | |
| KR910001057A | Republic of Korea | A | |
| PT94443A | Portugal | A | |
| JPH0348699A | Japan | A | |
| EP0404097A3This record | European Patent Office (EPO) | A3 | |
| AU639241B2 | Australia | B2 | |
| EP0404097B1 | European Patent Office (EPO) | B1 | |
| AT142230T | Austria | T | |
| DE59010480D1 | Germany | D1 | |
| GR3021109T3 | Greece | T3 | |
| ES2093623T3 | Spain | T3 | |
| US5591828A | United States of America | A | |
| DK0404097T3 | Denmark | T3 | |
| PT94443B | Portugal | B | |
| IE76715B1 | Ireland | B1 | |
| RU2096459C1 | Russian Federation | C1 | |
| KR0183980B1 | Republic of Korea | B1 | |
| JP2978210B2 | Japan | B2 | |
| CA2019559C | Canada | C |
46 legal events, as 7 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Ep patent expiredExpiredEUP | EUP | DK | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Discontinued because of reaching the maximum lifetime of a patentV4 | V4 | NL | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Fr: translation filedCORRECTIONSET | ET | EP | |
| Validation in greece3021109FG4A | FG4A | GR | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0404097
- Publication, DOCDB
- 0404097
- Publication, EPODOC
- EP0404097
- Application
- 111640
- Application, DOCDB
- 90111640
- Application, EPODOC
- EP19900111640
Titles3
- German
- Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
- English
- Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
- French
- Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
Classification
- CPC, 5
- C07K16/468
- C12N15/11
- A61K38/00
- C07K16/3007
- A61P35/00
- IPC, 18
- A61K31 00
- A61K38 00
- A61K39 395
- A61P35 00
- C07K1 22
- C07K14 00
- C07K14 705
- C07K16 00
- C07K16 18
- C07K16 30
- C07K16 46
- C07K19 00
- C12N5 10
- C12N15 09
- C12N15 13
- C12P21 00
- C12P21 08
- C12R1 91
Designated states1
- Contracting states, 1
- Sweden